• Je něco špatně v tomto záznamu ?

Hemopatch® is effective and safe to use: real-world data from a prospective European registry study

C. Lombardo, S. Lopez-Ben, U. Boggi, P. Gutowski, T. Hrbac, L. Krska, J. Marquez-Rivas, D. Russello, E. York, M. Zacharias

. 2022 ; 74 (5) : 1521-1531. [pub] 20220820

Jazyk angličtina Země Itálie

Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc22024331

Surgical procedures are often impeded by bleeding and/or leakage of body fluids. These complications cannot always be resolved by conventional surgical techniques. Hemopatch® is a hemostatic patch that also functions as a sealant. Here we document the effectiveness and safety of Hemopatch® for routine procedures of multiple surgical disciplines. To this end, we performed a prospective, multicenter, single-arm, observational registry study. Patients were eligible if they had received Hemopatch® during an open or minimally invasive procedure in one of these specialties: hepatobiliary, cardiovascular, urological, neurological/spinal, general, or lung surgery. Patients were excluded if they had a known hypersensitivity to bovine proteins or brilliant blue, intraoperative pulsatile or severe bleeding and/or infection at the target application site (TAS). The primary endpoint for intraoperative effectiveness was hemostasis assessed as the percentage of patients achieving hemostasis within 2 min and the percentage of patients achieving hemostasis without re-bleeding at the time of surgical closure. The registry enrolled 621 patients at 23 study sites in six European countries. Six hundred twenty patients had completed follow-up information. Hemostasis within 2 min was achieved at 463 (74.5%) of all 621 TASs. Hemostasis without re-bleeding was observed at 620 (99.8%) TASs. Adverse events were reported in 64 patients (10.3%). This Hemopatch® registry shows that Hemopatch® efficiently establishes hemostasis and sealing in a variety of surgical specialties, including minimally invasive procedures. Furthermore, we provide evidence for the safety of Hemopatch® across all the specialties included in the registry. This study is registered at clinicaltrials.gov: NCT03392662.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024331
003      
CZ-PrNML
005      
20221031100406.0
007      
ta
008      
221017s2022 it f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s13304-022-01353-y $2 doi
035    __
$a (PubMed)35986865
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Lombardo, Carlo $u Division of General and Transplant Surgery, University of Pisa, Pisa, Italy. carlolombardomd@gmail.com $1 https://orcid.org/http://orcid.org/0000000344111143
245    10
$a Hemopatch® is effective and safe to use: real-world data from a prospective European registry study / $c C. Lombardo, S. Lopez-Ben, U. Boggi, P. Gutowski, T. Hrbac, L. Krska, J. Marquez-Rivas, D. Russello, E. York, M. Zacharias
520    9_
$a Surgical procedures are often impeded by bleeding and/or leakage of body fluids. These complications cannot always be resolved by conventional surgical techniques. Hemopatch® is a hemostatic patch that also functions as a sealant. Here we document the effectiveness and safety of Hemopatch® for routine procedures of multiple surgical disciplines. To this end, we performed a prospective, multicenter, single-arm, observational registry study. Patients were eligible if they had received Hemopatch® during an open or minimally invasive procedure in one of these specialties: hepatobiliary, cardiovascular, urological, neurological/spinal, general, or lung surgery. Patients were excluded if they had a known hypersensitivity to bovine proteins or brilliant blue, intraoperative pulsatile or severe bleeding and/or infection at the target application site (TAS). The primary endpoint for intraoperative effectiveness was hemostasis assessed as the percentage of patients achieving hemostasis within 2 min and the percentage of patients achieving hemostasis without re-bleeding at the time of surgical closure. The registry enrolled 621 patients at 23 study sites in six European countries. Six hundred twenty patients had completed follow-up information. Hemostasis within 2 min was achieved at 463 (74.5%) of all 621 TASs. Hemostasis without re-bleeding was observed at 620 (99.8%) TASs. Adverse events were reported in 64 patients (10.3%). This Hemopatch® registry shows that Hemopatch® efficiently establishes hemostasis and sealing in a variety of surgical specialties, including minimally invasive procedures. Furthermore, we provide evidence for the safety of Hemopatch® across all the specialties included in the registry. This study is registered at clinicaltrials.gov: NCT03392662.
650    _2
$a zvířata $7 D000818
650    _2
$a krvácení při operaci $7 D016063
650    _2
$a skot $7 D002417
650    _2
$a hemostáza chirurgická $x metody $7 D006488
650    12
$a hemostatika $x škodlivé účinky $7 D006490
650    _2
$a lidé $7 D006801
650    _2
$a prospektivní studie $7 D011446
650    _2
$a registrace $7 D012042
650    12
$a obory chirurgické $7 D013043
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Lopez-Ben, Santiago $u Hepatobiliary and Pancreatic Surgery Unit, Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain $1 https://orcid.org/http://orcid.org/0000000251929966
700    1_
$a Boggi, Ugo $u Division of General and Transplant Surgery, University of Pisa, Pisa, Italy $1 https://orcid.org/http://orcid.org/0000000275055896
700    1_
$a Gutowski, Piotr $u Clinic for Vascular Surgery, Samodzielny Public Hospital, Szczecin, Poland
700    1_
$a Hrbac, Tomas $u Neurosurgical Clinic, University Hospital, Ostrava-Poruba, Czech Republic $1 https://orcid.org/http://orcid.org/0000000264019849
700    1_
$a Krska, Lukas $u Neurosurgical Clinic, University Hospital, Ostrava-Poruba, Czech Republic
700    1_
$a Marquez-Rivas, Javier $u Department of Pediatric Surgery, Hospital Universitario Virgen del Rocio, Seville, Spain $1 https://orcid.org/http://orcid.org/0000000251364723
700    1_
$a Russello, Domenico $u General Surgery Unit, Azienda Ospedaliera per l'Emergenza Cannizzaro, Catania, Italy $1 https://orcid.org/http://orcid.org/0000000177574334
700    1_
$a York, Elisa $u Department of Surgery, Hospital La Paz, Madrid, Spain
700    1_
$a Zacharias, Mario $u Clinic for Urology, Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany
773    0_
$w MED00208705 $t Updates in surgery $x 2038-3312 $g Roč. 74, č. 5 (2022), s. 1521-1531
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35986865 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100403 $b ABA008
999    __
$a ok $b bmc $g 1854195 $s 1175621
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 74 $c 5 $d 1521-1531 $e 20220820 $i 2038-3312 $m Updates in surgery $n Updates Surg $x MED00208705
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...